deltatrials
Completed PHASE2 NCT00550875

Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis

A Randomised Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Sublingual Immunotherapy With a Depigmented and Polymerized Grass Pollen Extracts in Patients Suffering From Allergic Rhinoconjunctivitis.

Sponsor: Laboratorios Leti, S.L.

Conditions Allergic Rhinoconjunctivitis
Interventions Grass pollen allergenic extract (L. perenne-C. dactylon ) placebo
Updated 5 times since 2017 Last updated: Jul 12, 2011 Started: Jun 30, 2007 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This PHASE2 trial investigates Allergic Rhinoconjunctivitis and is currently completed. Laboratorios Leti, S.L. leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Laboratorios Leti, S.L.
Data source: Laboratorios Leti, S.L.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Mowbray, South Africa